Investment analysts at Royal Bank Of Canada began coverage on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a research report issued to clients and investors on Thursday, The Fly reports. The firm set an “outperform” rating on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the stock. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Wednesday, August 30th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $35.00 price objective on shares of AnaptysBio in a research report on Tuesday. Credit Suisse Group upped their price objective on shares of AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, August 25th. Finally, Robert W. Baird initiated coverage on shares of AnaptysBio in a research report on Monday, July 10th. They issued an “outperform” rating and a $36.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $36.33.

Shares of AnaptysBio (NASDAQ:ANAB) traded down 3.93% during midday trading on Thursday, reaching $31.31. 397,565 shares of the company traded hands. AnaptysBio has a 12-month low of $15.17 and a 12-month high of $33.58. The company has a 50-day moving average of $32.13 and a 200 day moving average of $27.21. The firm’s market capitalization is $636.91 million.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.29. The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. On average, equities analysts forecast that AnaptysBio will post ($1.96) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “AnaptysBio, Inc. (ANAB) Now Covered by Analysts at Royal Bank Of Canada” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/14/anaptysbio-inc-anab-now-covered-by-analysts-at-royal-bank-of-canada.html.

In other news, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Insiders sold a total of 1,133,940 shares of company stock valued at $24,223,316 over the last ninety days.

Several institutional investors have recently added to or reduced their stakes in ANAB. Frazier Management LLC bought a new position in shares of AnaptysBio during the 1st quarter valued at approximately $102,354,000. Perceptive Advisors LLC bought a new position in shares of AnaptysBio during the 1st quarter valued at approximately $24,474,000. Marshall Wace North America L.P. bought a new position in shares of AnaptysBio during the 1st quarter valued at approximately $6,924,000. MARSHALL WACE ASIA Ltd bought a new position in shares of AnaptysBio during the 1st quarter valued at approximately $6,924,000. Finally, Artal Group S.A. grew its position in shares of AnaptysBio by 459.4% during the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after acquiring an additional 205,310 shares during the period. 71.35% of the stock is owned by hedge funds and other institutional investors.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

The Fly

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.